The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis

Carrera, Fernando; Oliveira, Lino Pinto de; Maia, Pedro; Mendes, Teresa; Ferreira, C

doi:10.1093/ndt/gfl387

Cited by 18 publications

(19 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased specific activity of darbepoetin alfa compared with rHuEPO was also reported in human clinical studies [56]. In humans administered darbepoetin alfa with a Q2W (every other week) dosing regimen, the same total dosage could successfully maintain Hb levels in renal anemic dialysis patients in comparison with QW (weekly) administration of the drug [57]. Similarly, in the predialysis population, QM (monthly) administration of the drug maintained Hb concentration at the same total dose in comparison with Q2W administration [58].…”

Section: Successful Development Of Darbepoetin Alfamentioning

confidence: 73%

Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact

Kiss¹,

Elliott

Jedynasty³

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Cloning of the human erythropoietin (EPO) gene and development of the first recombinant human erythropoietin (rHuEPO) drug were truly breakthroughs. This allowed a deeper understanding of the structure and pharmacology of rHuEpo, which in turn inspired the discovery and development of additional erythropoiesisstimulating agents (ESAs). In vivo specific activity and serum half-life of rHuEPO are influenced by the amount and structure of the attached carbohydrate. Increased numbers of sialic acids on carbohydrate attached to rHuEPO correlated with a relative increase in in-vivospecific activity and increased serum half-life. The effect of increasing the number of sialic-acid-containing carbohydrates on in-vivo-specific activity was explored. Initial research focused on solving the problem of how the protein backbone could be engineered so a cell would add more carbohydrate to it. Additional work resulted in darbepoetin alfa, a longer-acting molecule with two additional carbohydrate chains.

show abstract

Section: Successful Development Of Darbepoetin Alfamentioning

confidence: 73%

Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact

Kiss¹,

Elliott

Jedynasty³

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…administration of ESAs to dialysis patients (15). Several earlier studies demonstrated that darbepoetin-alpha can be given once every 2 weeks (Q2W) and maintains hemoglobin levels in hemodialysis patients , in 2006 the results of the study done by Carrera et al (20), fully support the practical use of the i.v. Q2W darbepoetin-alpha regimen in stable HD patients switched from once weekly dosing.…”

Section: Discussionmentioning

confidence: 89%

“…Thirty (83%) of those evaluable patients successfully maintained the target haemoglobin with no or minimal dose increased required to maintain the required hemoglobin concentration , while their conversion regimen was unsuccessful in 6 patients and was concluded that darbepoetin-alpha administered once monthly, maintained hemoglobin effectively and safely in most dialysis patients stabilized previously on once every 2 weeks dosing however the median weekly dose of darbepoetin-alpha increased from (15 units , CI =11. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] at the start of the study to (21.88 units, CI =12. 31-31.25) .…”

Section: Discussionmentioning

confidence: 99%

Monthly Administration of Darbepoetin Alpha in Saudi Hemodialysis Patients: is it a Practical Regimen?

et al. 2010

View full text Add to dashboard Cite

show abstract

“…15 Several earlier studies demonstrated that darbepoetin alfa can be given once every 2 weeks and maintains Hgb levels in hemodialysis patients. In 2006, the results of the study done by Carrera et al, 20 fully supported the practical use of the once every-2-week IV darbepoetin alfa regimen in stable HD patients switched from once-weekly dosing.…”

Section: Discussionmentioning

confidence: 91%

The efficacy of monthly administration of darbepoetin alfa in Saudi hemodialysis patients

Alsaran

Sabry

Abdulghafour

et al. 2009

Dialysis & Transplantation

View full text Add to dashboard Cite

BACKGROUNDErythropoiesis‐stimulating agents have improved the outcome and quality of life in patients with chronic kidney disease.OBJECTIVEWe investigated the efficacy and safety of conversion of hemodialysis patients from epoetin beta to darbepoetin alfa administered once a month.PATIENTS AND METHODSThe study included 26 patients. Their mean age was 47.0 6 17.13 years with a mean hemodialysis duration of 55.8 ± 14.0 months. The study was carried out in 2 consecutive phases of 12 weeks each. The mean initial dose of darbepoetin was 57 ± 10.0 mg biweekly. After maintaining target hemoglobin (Hgb) levels—(11–12 g/L)—with the biweekly injections, we shifted our patients to a once‐monthly dose schedule.RESULTSThe mean weekly darbepoetin dose increased from 28.75 ± 4.2 mg during the biweekly phase to 38.5 ± 3.9 mg after switching to the monthly protocol (the mean conversion ratio changed from 309:1 to 256:1). The mean Hgb level was 10.81 ± .86 g/L at the start of the study and 10.86 ± .76 g/L at the end of 6 months.CONCLUSIONOur experience with darbepoetin alfa reveals that it is effective and safe for the treatment of anemia in hemodialysis patients even at monthly dose intervals.

show abstract

The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis

Cited by 18 publications

References 4 publications

Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact

Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact

Monthly Administration of Darbepoetin Alpha in Saudi Hemodialysis Patients: is it a Practical Regimen?

The efficacy of monthly administration of darbepoetin alfa in Saudi hemodialysis patients

Contact Info

Product

Resources

About